Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SymBio and Eisai discontinue Japanese phase II trial of Treakisym

Nov. 4, 2013

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Oct. 30, 2013

Vaccine targeting IDO safe and well tolerated in first-in-human study

Oct. 29, 2013

Mologen files application in Belgium to conduct trial in small cell lung cancer

Oct. 29, 2013

FDA grants orphan drug designation to Aduro's immunotherapy for pancreatic cancer

Oct. 23, 2013

Antibody DCBPR-01101 targets globo H for breast cancer treatment

Oct. 23, 2013

Updated immunological results published from phase I evaluation of AE37 prostate cancer vaccine

Oct. 23, 2013

FDA submission for Arzerra in previously untreated CLL

Oct. 22, 2013

Seattle Genetics begins phase I study of SGN-LIV1A

Oct. 22, 2013

Team of Japanese researchers designs novel antibodies for multiple myeloma

Oct. 22, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...